Current Report Filing (8-k)
September 13 2022 - 2:46PM
Edgar (US Regulatory)
0000890821
false
0000890821
2022-09-09
2022-09-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
September
9, 2022
Date
of Report (Date of earliest event reported)
Enveric
Biosciences, Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-38286 |
|
95-4484725 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
Enveric
Biosciences, Inc.
4851 Tamiami Trail N, Suite 200
Naples, FL 34103
(Address of principal executive offices) (Zip code)
Registrant’s
telephone number, including area code: (239) 302-1707
N/A
(Former name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
stock, par value $0.01 per share |
|
ENVB |
|
The
Nasdaq Stock Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
September 9, 2022, Robert Dickey IV was
appointed as the Chief Financial Officer (“CFO”) of the Company, to serve on an interim basis, effective September 9, 2022.
Robert Dickey IV, age 66, has served
as Managing Director at Foresite Advisors since March 2020 and was previously a Managing Director at Danforth Advisors from August
2018 to March 2020. Foresite Advisors provides finance support and strategy for life science companies, including CFO advisory,
financial analysis, and transactional support/execution for fundraising and M&A. Mr. Dickey has served on the board of
directors of Angiogenex, Inc., a publicly traded biopharmaceutical company, since 2020 and SFA Therapeutics, a privately held
company developing microbiome-derived therapies, since 2022. He has been on the leadership team of Cell One Partners, a
strategic consulting services company focused on cell and gene therapy since 2018 and BCI LifeSciences, an advisory firm
affiliated with a broker-dealer, since 2021. Mr. Dickey served as a member on the board of directors and audit committee
chair at Emmaus Life Sciences, Inc., a publicly traded biopharmaceutical company, from 2018 to 2022 and as a member on the
board of directors of Sanuthera, Inc., a privately held medical device company, from 2013 to 2017. Previously, he was
employed as CFO of Motif Bio Plc., a NASDAQ and London AIM exchange-listed antibiotics company, from January 2017 to February 2018.
He also was previously employed with several other biotechnology companies, including as the CFO of Tyme Technologies, Inc.
from May 2015 to January 2017, the CFO of NeoStem, Inc. from August 2013 to January 2015 and the Senior Vice President of Hemispherx
Biopharma, Inc. from November 2008 to August 2013. Prior to that time, among other things, Mr. Dickey served as a Managing Director
at Legg Mason Wood Walker, Inc., Senior Vice President at Lehman Brothers and Co-Founder/Partner at The Middle Market
Group, an affiliate of Lehman Brothers. He received his undergraduate degree from Princeton University and an M.B.A. from The
Wharton School of the University of Pennsylvania.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
September 13, 2022 |
ENVERIC
BIOSCIENCES, INC. |
|
|
|
By: |
/s/
Joseph Tucker |
|
|
Joseph
Tucker |
|
|
Chief
Executive Officer |
Ameri (NASDAQ:AMRH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ameri (NASDAQ:AMRH)
Historical Stock Chart
From Apr 2023 to Apr 2024